European Patent granted for BUPI

STOCKHOLM, October 19, 2016 -- Moberg Pharma AB (OMX: MOB) announced that the
European Patent Office (EPO) has issued Patent No. 2701681 which protects BUPI,
currently in development for oral mucositis.
The new patent covers pharmaceutical compositions comprising a local anesthetic,
such as bupivacaine, for local administration to the mouth or throat. The patent
also protects lozenge formulations of a local anesthetic for use in the
treatment of oral mucositis in cancer patients. This patent is expected to
provide coverage through at least 2031. Additional patent applications are
pending in the United States and Canada.

“This patent provides Moberg with important intellectual property protection for
BUPI, our lozenge formulation of bupivacaine for pain management of oral
mucositis in cancer patients,” commented Peter Wolpert, Moberg Pharma’s CEO.
“This issuance of this patent is an important milestone for the BUPI development
program and part of our overall strategy to establish a broad portfolio of
patent claims to protect our proprietary products.”

Earlier in 2016, the Company announced positive Phase 2 results with BUPI in
treating pain associated with oral mucositis in patients with head and neck
cancer undergoing radiotherapy. The primary endpoint was met with high
statistical significance. The Company is moving forward with one Phase 3 trial
to be conducted in Europe, co-funded by a grant from Eurostars. A second Phase 3
study will be conducted in India, financed by Moberg’s partner Cadila
Pharmaceuticals. The agreement with Cadila in combination with the Eurostars
grant means that Moberg’s investment for the BUPI phase 3 program is
substantially reduced.

About this information
This information is information that Moberg Pharma AB is obliged to make public
pursuant to the EU Market Abuse Regulation. The information was submitted for
publication, through the agency of the contact person set out above, at 8.30 CET
on October 19, 2016.

About Oral Mucositis and BUPI
Oral mucositis (“OM)” is a painful inflammation and ulceration of the mucous
membranes lining the mouth. OM is a common and often debilitating complication
of cancer treatment which affects 80% of patients with head and neck cancer
receiving radiotherapy, almost all patients undergoing bone marrow
transplantation, and a wide range of patients receiving chemotherapy. OM makes
the patient less likely to comply with their cancer treatment, increases
mortality and morbidity and contributes to rising health care costs. In the
U.S., every year approximately 400 000 patients suffer from OM during cancer
therapy.

The patent protected BUPI technology encompasses novel lozenge formulations of
bupivacaine, a local anesthetic with a well-established long acting effect,
currently available on the market for other indications as an injectable. In
Phase 2, the group treated with BUPI had 31% reduction in pain in mouth or
pharynx compared to standard pain treatment (p=0.0032). The difference measured
in the mouth only was even more pronounced - BUPI provided 50% additional pain
reduction compared to standard treatment (p=0.0002).
For additional information, please contact:
Peter Wolpert, CEO, Phone: +46 707 35 71 35, E-mail:
peter.wolpert@mobergpharma.se
Kjell Rensfeldt, VP R&D, Phone: +46 707 12 4532, E-mail:
kjell.rensfeldt@mobergpharma.se
About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with
OTC sales operations in the U.S. and a distributor network in more than 40
countries. The company’s portfolio includes the OTC brands Kerasal®, Kerasal
Nail®, Balmex®, NewSkin®, Domeboro®, Fiber Choice® and PediaCare®. Kerasal Nail®
(Emtrix® or Nalox™ in certain markets) is a leading OTC treatment of nail
disorders in the U.S., Canada as well as in several markets in EU and Southeast
Asia. The company is growing organically as well as through acquisitions.
Internal development programs focuses on innovative drug delivery of proven
compounds and include two clinical stage assets, MOB-015 (onychomycosis) and
BUPI (pain management in oral mucositis). Moberg Pharma has offices in Stockholm
and New Jersey and the company’s shares are listed on the Small Cap list of the
NASDAQ OMX Nordic Exchange Stockholm (MOB.ST).